Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: a Translational Study of S1602

Project: Research project

Description

The long-term goal of this research is to determine the genetic, cellular, and immune-mediated mechanisms associated with BCG therapy to augment current treatments, design novel therapies, and better risk stratify patients and Veterans with bladder cancer. This proposal leverages the resources of the randomized, phase III trial from the Southwest Oncology Group 1602 (S1602) involving over 900 patients treated with BCG.
StatusActive
Effective start/end date7/1/186/30/21

Funding

  • U.S. Army Medical Research and Materiel Command (W81XWH1810257)

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Veterans
Therapeutics
Research